ArticleDiscover oncology2025
The predictive value of dynamic changes in neutrophil-to-lymphocyte ratio for the prognosis of hepatocellular carcinoma patients treated with transarterial chemoembolization.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Early Changes in the Neutrophil-to-Lymphocyte Ratio are Associated with Conversion Outcomes in Advanced Hepatocellular Carcinoma Treated with HAIC-Based Triple Therapy.Journal of hepatocellular carcinoma · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInflammatory biomarkers, including the neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR), serve as crucial indicators of tumor-immune system interactions and reflect the tumor immune microenvironment. Although the prognostic significance of baseline inflammatory indices in oncology is well-recognized, the correlation between the temporal variations of these biomarkers during transarterial chemoembolization (TACE) for hepatocellular carcinoma (HCC) and therapeutic response warrants further investigation.
methodsThis retrospective cohort study analyzed clinical data from 157 HCC patients undergoing TACE between 2021 and 2023. Preoperative NLR, postoperative NLR, and three-month postoperative NLR values were collected to assess tumor response and prognosis. Predictive factors for the disease control rate at three months were identified using logistic regression. Subsequently, patients were stratified based on the optimal cut-off value derived from ROC curve analysis, followed by survival and prognostic analyses.
resultsThe longitudinal change in NLR from preoperative to three-month follow-up, as opposed to the baseline NLR value alone, emerged as a significant predictor of disease control. And an elevated NLR trajectory was robustly associated with tumor progression. Furthermore, increased NLR changes were correlated with inferior overall survival outcomes (median survival: 26.326 vs. 20.294 months, p = 0.005).
conclusionThe dynamic NLR changes demonstrate significant correlation with therapeutic outcomes in HCC patients receiving TACE. This biomarker exhibits potential as a prognostic indicator for identifying TACE-responsive patients, thereby offering valuable guidance for subsequent therapeutic decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.